肝脏疾病

互动

阅读原始引用

是的，我们与卫生部、马里人民药房（Pharmacie Populaire du Mali）以及国民议会保持合作。

Oui, auprès du ministère de la santé, pharmacie populaire du Mali, de l'assemblée nationale.

互动

阅读原始引用

社区肝脏联盟的倡导工作包括：与CMS（医疗保险和医疗补助服务中心）的互动、参与公众意见征询机会（包括与医疗保险药品价格谈判相关的机会）、与政策制定者合作推动PBM（药房福利管理机构）改革，以及向监管利益相关方宣传定价决策对慢性和罕见肝病患者的实际影响。

The Community Liver Alliance represents patient interests to regulators and policymakers responsible for advising on and determining drug pricing. We engage at the federal and state levels to ensure that the lived experiences of people affected by liver disease inform policy decisions related to drug access, affordability, and reimbursement. Our advocacy includes engagement with CMS, participation in public comment opportunities (including those related to Medicare Drug Price Negotiation), collaboration with policymakers on PBM reform, and education of regulatory stakeholders about the real-world impact of pricing decisions on patients with chronic and rare liver diseases. We elevate patient and caregiver voices to ensure pricing policies balance innovation with equitable and timely access to life-saving therapies.

行动与倡导

阅读原始引用

每年，我们向国家政府和都道府县政府提交下一财政年度的预算申请。

毎年、国や都道府県に対し次年度予算要望書を提出。

行动与倡导

阅读原始引用

我们与FDA（食品和药物管理局）、国会及白宫合作，共同制定影响肝病患者的联邦政策。

We work with FDA, Congress, and the White House on federal policies that affect liver patients.